Ketha Mead accepts new patients on Medical News Today.
Ketha Mead
Be the first to review this provider!
Moscow, ID
Accepting new patients
Clinical Overview
Ketha Mead works in Moscow, ID as
Office Locations
-
Office1350 Troy Rd Ste 2, Moscow, ID 83843
Patient Experience & Satisfaction
Be the first to leave a review
How likely are you to recommend Ketha Mead?
Step 1 of 3
Your review of Ketha Mead
50 characters remaining
1000 characters remaining
Was this a Telehealth appointment?
(This will display with your review)
Your email is used to confirm your review and will NOT appear in the review.
This name will appear with your review. If left blank, we'll use "Anonymous".
RVO Health property, Medical News Today, is owned by RVO Health. Please review our terms of use for more.
Help other patients find the right care by sharing a few more details about your visit.
Last step! Confirm your email.
We've sent an email to
Once you confirm, you can close this window.
Thank you for your review!
Your review has been confirmed and will be published after verification.
Thank you for your review!
We've sent a confirmation email. Your review will appear after you confirm it.
Please allow up to 30 seconds for the email to arrive. Don't see it? Make sure to check your 'spam' and 'updates' folder. Once you've confirmed your review, you can close this window.
Medical Expertise & Background
Specialties*
Developmental Therapy
- *Medical News Today does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
Common Patient Questions
Ketha Mead's office is located at 1350 Troy Rd Ste 2 Moscow, ID 83843. Get a map and directions to Ketha Mead's office here.
Ketha Mead does not have any reviews yet.
Claim Your Profile
Are you Ketha Mead?
Know Before You Go
Preventive care: what doctors want you to know
Preventive care can help identify current or future health and medical concerns before they become major.
Featured Stories
A drug candidate created with AI reduced biological age markers across 6 proteomic clocks in a phase 2a trial, suggesting that it may help reverse predicted biological aging.
A recent study has found that elevated NT-proBNP levels could help predict the risk of heart disease in older adults. Experts weigh in on whether the test could eventually have a role in routine cardiovascular risk assessment.
Daraxonrasib (Rasonque), recently approved for the treatment of metastatic pancreatic cancer, is also showing promise in the treatment of lung cancer in early trials.
